Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing.
Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. Giving docetaxel together with erlotinib may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of erlotinib when
given together with docetaxel in treating patients with solid tumors and to see how well they
work in treating patients with advanced non-small cell lung cancer. (Phase I portion of the
study treating patients with any solid tumor was completed as of 12/01/2004)
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of California, Davis
Collaborators:
Aventis Pharmaceuticals Genentech, Inc. National Cancer Institute (NCI)